Edward Case
Psychiatry · Patton, CANPI 1407808785
Payments from drug & device makers
Across 536 payments — averaging $27.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Corium, LLC$2K
- Otsuka America Pharmaceutical, Inc.$761
- Teva Pharmaceuticals USA, Inc.$757
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$749
- Sunovion Pharmaceuticals Inc.$651
- plus $3K from 13 others
What the payments were for
- Consulting fees$3602%
- Speaking & faculty fees$6,18042%
- Food & beverage$7,76753%
- Education$3983%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 191 | $6,728 |
| Corium, LLC | 29 | $2,443 |
| Otsuka America Pharmaceutical, Inc. | 67 | $761 |
| Teva Pharmaceuticals USA, Inc. | 40 | $757 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $749 |
| Sunovion Pharmaceuticals Inc. | 33 | $651 |
| Neurocrine Biosciences, Inc. | 24 | $483 |
| E.r. Squibb & Sons, L.L.C. | 18 | $422 |
| Axsome Therapeutics, Inc. | 17 | $420 |
| Lundbeck LLC | 23 | $413 |
| Avanir Pharmaceuticals, Inc. | 22 | $256 |
| Alkermes, Inc. | 12 | $234 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $149 |
| Indivior Inc. | 4 | $88 |
| Shire North American Group Inc | 3 | $55 |
| Jazz Pharmaceuticals Inc. | 3 | $55 |
| Merck | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,706 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 19 | $28,803 |
| RexultiBrexpiprazole | 17 | $25,064 |
| BelsomraSuvorexant | 46 | $22,013 |
| Asenapine Maleate | 11 | $4,448 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 57 | $1,719 |
| Buspirone Hcl | 57 | $878 |
| Prazosin Hcl | 19 | $740 |
| Olanzapine | 19 | $697 |
| Duloxetine Hcl | 31 | $625 |
| Quetiapine Fumarate | 35 | $564 |
| Propranolol Hcl ErPropranolol Hcl | 17 | $539 |
| Gabapentin | 50 | $508 |
| Clonazepam | 45 | $432 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 30 | $393 |
| Lamotrigine | 21 | $392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $6,728 | $28,80319 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $761 | $25,06417 claims |
| MerckBelsomra | $14 | $22,01346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Patton
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.